Peptide Planet Exclusive
Compare two peptide companies
Side-by-side scorecard on pipeline depth, trial mix, enrollment, and upcoming catalysts. No other peptide-intelligence platform ships this — bookmark or share the URL to send this exact comparison.
Scorecard summary
Across 9 tracked metrics, Eli Lilly leads on 1 and Novo Nordisk leads on 2. The remaining 6 are ties. Shared indications: Type 2 Diabetes, Obesity, Cardiometabolic.
NYSE: LLY · Mega cap
Eli Lilly
Indianapolis, IN, USA
Incretin therapies (GLP-1 / GIP / glucagon triagonists)
Global pharmaceutical developing peptide-based incretin therapies including tirzepatide and next-generation triagonists.
NYSE: NVO · Mega cap
Novo Nordisk
Bagsværd, Denmark
GLP-1 analogs, amylin, and combination peptides
Diabetes and obesity leader with semaglutide franchise and combination peptides in late-stage development.
| Metric | LLY | NVO | Δ |
|---|---|---|---|
Pipeline programs Peptide-related programs disclosed | 6 | 8 | -2 |
Unique peptides in trials Distinct molecules with active NCT records | 2 | 2 | |
Phase 3 trials Late-stage registrational studies | 3 | 3 | |
Phase 2 trials Efficacy / dose-finding studies | 0 | 0 | |
Active trials Recruiting or ongoing | 1 | 1 | |
Total tracked trials All phases, all statuses | 3 | 3 | |
Cumulative enrollment Sum of planned patients across tracked trials | 6,518 | 6,578 | -60 |
Catalysts next 12 mo Upcoming readouts, PDUFAs, AdComs | 1 | 1 | |
High-impact catalysts Flagged 'High' importance | 2 | 1 | +1 |
Only LLY
- MASH
Shared focus
- Type 2 Diabetes
- Obesity
- Cardiometabolic
Only NVO
None
LLY · peptides in tracked trials
- TirzepatideApproved
- RetatrutidePhase 3
NVO · peptides in tracked trials
- SemaglutideApproved
- CagrilintidePhase 3
Go deeper
Get alerts when either company files a new trial or catalyst
Pro members get email + in-app alerts for LLY and NVO.